American Academy of Neurology (AAN)
75^th Annual Meeting in Boston, Mass. (April 22-28, 2023)

• Characteristics and treatment response to onabotulinumtoxinA of patients from CD-PROBE with anterocollis and retrocollis.
  

  Dashtipour K, Jankovic J, Charles D, Mehta S, Schwartz M, Sadeghi M

• Spinocerebellar ataxia 21 and phenotypic variability within a single family.
  

  Hull M, Parnes M, Jankovic J

• Apathy and Parkinson's disease motor phenotypes: A preliminary study.
  

  Lenka A, Gazes Y, Vanegas-Arroyave N

• Precision neurology for dementia.
  

  Shulman J, Vanegas-Arroyave N, Fong J, Elsea S, Lin C, Saade H, et al.

Movement Disorder Society (MDS)
26^th International Congress of Parkinson's Disease and Movement Disorders in Madrid, Spain (Sept. 15-18, 2022)

• Characteristics and treatment response to onabotulinumtoxinA of patients from CD-PROBE with anterocollis subtype of cervical dystonia.
  

  Dashtipour K, Jankovic J, Charles D, Mehta S, Schwartz M, Sadeghi M

• Characteristics and treatment response to onabotulinumtoxinA of patients from CD-PROBE with retrocollis subtype of cervical dystonia.
  

  Dashtipour K, Jankovic J, Charles D, Mehta S, Schwartz M, Sadeghi M

• Spinocerebellar ataxia 21 and phenotypic variability within a family.
  

  Hull M, Parnes M, Jankovic J

• Neuroanatomical underpinnings of apathy in Parkinson's disease.
  

  Le Heron C, Huey E, Vanegas-Arroyave N, Gazes Y, Lee S

• How does head tremor in cervical dystonia change with head position?
  

  Vu J, Cisneros E, Zhao J, Jankovic J, Factor S, Goetz C, et al.

International Neurotoxin Association (INA)
Toxins 2022 6^th International Conference in New Orleans, La. (July 27-30, 2022)

• Characteristics and treatment response to onabotulinumtoxinA of patients from CD-PROBE with anterocollis and retrocollis.
  

  Dashtipour K, Jankovic J, Charles D, Mehta S, Schwartz M, Sadeghi M

American Academy of Neurology (AAN)
74^th Annual Meeting in Seattle, Wash. (April 2-7, 2022)

• Neutralizing antibody conversion with onabotulinumtoxinA from global studies across multiple indications in nearly 30,000 patient records: A meta-analysis.
  [Previously Presented]
  

  Jankovic J, Carruthers J, Naumann M, Boodhoo T, Gupta S, Attar M, et al.

• A phase 3 trial evaluating the efficacy, duration of effect, and safety of daxibotulinumtoxinA for injection in the treatment of cervical dystonia.
  

  Jankovic J, Comella C, Hauser RA, Patel AT, Gross TM, Rubio RG, et al.

Movement Disorder Society (MDS)
Virtual International Congress of Parkinson's Disease and Movement Disorders. (Sept. 17-22, 2021)

• Pilot study to evaluate pimavanserin for the treatment of motor and behavioral symptoms of Tourette syndrome.
  

  Billnitzer A, Jankovic J

• A phase 3 trial evaluating the efficacy, duration of effect, and safety of daxibotulinumtoxinA for injection in the treatment of cervical dystonia.
  

  Jankovic J, Comella C, Hauser RA, Patel AT, Gross TM, Rubio RG, et al.

• Tourette syndrome and driving.
  

  Makhoul K, Jankovic J

• Whole-exome sequencing in a movement disorders clinic.
  

  Shah C, Robak L, Hill EJ, Jankovic J

• The MJFF global genetic Parkinson's disease research resource.
  

  Vollstedt E-J, Aasly JO, Ahmad-Annuar A, Al Mubarak B, Alcalay RN, Alvarez V, et al.

American Academy of Neurology (AAN)
Virtual 2021 Annual Meeting (April 17-22, 2021)

• A phase 3 trial evaluating the efficacy, duration of effect, and safety of daxibotulinumtoxinA for injection in the treatment of cervical dystonia.
  

  Jankovic J, Comella C, Hauser RA, Patel AT, Gross TM, Rubio RG, et al.

International Neurotoxin Association (INA)
Virtual Conference (Jan. 16-17, 2021)

• Neutralizing antibody conversion with onabotulinumtoxinA from global studies across multiple indications in nearly 30,000 patient records: A meta-analysis.
  

  Jankovic J, Carruthers J, Naumann M, Boodhoo T, Gupta S, Attar M, et al.

• A phase 3 trial evaluating the efficacy, duration of effect, and safety of daxibotulinumtoxinA for injection in the treatment of cervical dystonia.
  

  Jankovic J, Comella C, Hauser RA, Patel AT, Gross TM, Rubio RG, et al.

• Duration of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naive subjects: Results from a phase III study.
  

  Mitsikostas DD, Dekundy A, Althaus M, Scheschonka A, Pagan F, Jankovic J

Movement Disorder Society (MDS)
Virtual International Congress of Parkinson's Disease and Movement Disorders. (Sept. 12-16, 2020)

• Cognitive differences between men and women with progressive supranuclear palsy.
  

  Bayram E, Jankovic J, Reich S, Marras C, Bordelon Y, Shprecher D, et al.

• Duration of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects: Results from a Phase III study.
  

  Pagan F, Dekundy A, Althaus M, Scheschonka A, Jankovic J, Mitsikostas D

American Academy of Neurology (AAN)
72^nd Annual Meeting in Toronto, Ontario, Canada (April 25 - May 1, 2020)

• Clinical and neuropsychological correlates of the TETRAS score in DBS patients.
  

  Bellows S, Combs J, Jimenez-Shahed J

• Addressing challenges of clinical comprehensive genetic testing in Parkinson's disease.
  

  Hill E, Deger J, Robak L, Rao S, Saade H, Ripperger B, et al.

• Treatment patterns in patients with essential tremor.
  

  Shah C, Jamal F, Jackson G, Sarwar A

American Academy of Neurology (AAN)
71^st Annual Meeting in Philadelphia, Penn. (May 4-10, 2019)

• Genome-wide association study meta-analysis for Parkinson disease motor subtypes.
  [Platform Presentation]
  

  Alfradique-Dunham I, Blauwendraat C, Al-Ouran R, von Coelln R, Tan M, Hill EJ, et al.

• Immunogenicity of daxibotulinumtoxinA for injection in adults with cervical dystonia from a phase 2 dose-escalation multicenter study.
  

  Brashear A, Truong DD, Comella CL, Jankovic J, Patel AT, Prawdzik G, et al.

• RECLAIM-DCP: A randomized, double-blind, placebo-controlled study of deutetrabenazine for the treatment of dyskinesia in cerebral palsy in children and adolescents.
  

  Claassen DO, Mink JW, Parnes M, Gordon MF, Barkay H, Wieman M, et al.

• Capturing Parkinson's disease heterogeneity with quantitative mobility measures.
  [Platform Presentation]
  

  Hill EJ, Alfradique-Dunham I, Mangleburg CG, Ripperger B, Stillwell A, Rao S, et al.

• Bradykinesia, mitochondrial myopathy and progressive ophthalmoplegia associated with a novel DNM1L mutation.
  

  Parnes M, Bashir HH, Jankovic J

Huntington Study Group (HSG)
Annual Meeting in Houston, Texas (Nov. 8-10, 2018)

• Real world experience with novel VMAT2 inhibitors.
  

  Niemann N, Jankovic J

• Clinical phenotype in carriers of intermediate alleles in the huntingtin gene.
  

  Savitt D, Jankovic J

Movement Disorder Society (MDS)
22^nd International Congress of Parkinson's Disease and Movement Disorders in Hong Kong, China (Oct. 5-9, 2018)

• Improvement in patient perceived quality of life with daxibotulinumtoxinA for injection in adults with cervical dystonia.
  

  Comella C, Brashear A, Jankovic J, Truong D, Patel A, Evatt M, et al.

• Predictors of alcohol responsiveness in dystonia.
  

  Junker J, Brandt V, Berman B, Vidailhet M, Roze E, Weissbach A, et al.

• Consensus for the measurement of the camptocormia angle.
  

  Margraf N, Wolke R, Granert O, Berardelli A, Berg D, Bloem B, et al.

• Integrated whole exome sequencing and chromosomal microarray in familial Parkinson's disease.
  

  Robak L, Du R, Yuan B, Gu S, Akdemir Z, Jankovic J, et al.

• Accuracy of the International Parkinson Disease and Movement Disorder Society progressive supranuclear palsy diagnostic criteria (IPD-MDS-PSP).
  

  Shoeibi A, Litvan I, Juncos J, Bordelon Y, Riley D, Reich S, et al.

• Genome-wide association study identifies common genetic variants associated with cervical dystonia.
  

  Sun Y, Hui Q, Perlmutter J, Ruehl S, Klein C, Jankovic J, et al.

• Erotophonophilia and severe impulse control disorder in a patient with Parkinson's disease.
  

  vander Linden C, Colle H, Colle D, Jankovic J

American Academy of Neurology (AAN)
70^th Annual Meeting in Los Angeles, Calif. (April 21-27, 2018)

• Whole exome sequencing in essential tremor.
  

  Alfradique-Dunham I, Robak L, Kaw A, Fagbongbe OI, Akdemir ZC, Young E, et al.

• Outcomes of week-24 completers and subjects who had follow-up beyond week 24 after a single treatment of daxibotulinumtoxinA for injection (RT002): Results of a phase 2, open-label (level II), dose escalating study in isolated cervical dystonia.
  

  Jankovic J, Truong D, Patel A, Brashear A, Evatt M, Rubio R, et al.

• Cervical dystonia and substance abuse.
  

  Mahajan A, Jankovic J, Marsh L, Patel A, Jinnah HA, Comella C, et al.

• Unilateral versus bilateral ventral intermediate nucleus deep brain stimulation for axial essential tremor symptoms.
  [Platform Presentation]
  

  Mitchell K, Peichel D, Wharen R, Okun M, Guthrie B, Uitti R, et al.

• Phenomenology of leg stereotypy syndrome.
  

  Niemann N, Jankovic J

• Is benign hereditary chorea really benign? Brain-lung-thyroid syndrome caused by NKX2-1 mutations.
  

  Parnes M, Bashir H, Jankovic J

• Levodopa induced dyskinesias in neurodegeneration with brain iron accumulation due to a heterozygous mutation in C19orf12.
  

  Savitt D, Jankovic J

Movement Disorder Society (MDS)
21^st International Congress of Parkinson's Disease and Movement Disorders in Vancouver, BC, Canada (June 4-8, 2017)

• Whole exome sequencing in essential tremor.
  

  Alfradique-Dunham I, Robak LA, Kaw A, Fagbongbe OI, Ternes K, Young E, et al.

• A phase 2, open-label, dose-escalating study to evaluate the safety and preliminary efficacy of daxibotulinumtoxinA for injection (RT002) in isolated cervical dystonia.
  [Previously Presented]
  

  Comella C, Jankovic J, Truong D, Brashear A, Patel A, Evatt M, et al.

• Clinical relevance of treatment with onabotulinumtoxinA in patients with cervical dystonia: Results from the CD probe study.
  

  Dashtipour K, Mari Z, Jankovic J, Adler C, Schwartz M, Brin M

• Treatable rare movement disorders.
  

  Gatto E, Jinnah H, Espay A, Jankovic J, Bhatia K, Rodriguez M, et al.

• A randomized, double-blind, placebo-controlled study of the D1 receptor antagonist ecopipam for children and adolescents with Tourette syndrome.
  

  Gilbert D, Murphy T, Jankovic J, Budman C, Black K, Kurlan R, et al.

• Results from a phase 1b multiple ascending-dose study of prx002, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson's disease.
  

  Jankovic J, Goodman I, Safirstein B, Schenk D, Kinney G, Koller M, et al.

• Leg stereotypy disorder: Phenomenology and prevalence.
  

  Jankovic J, Lotia M, York MK, Strutt AM

• Emotion regulation and neuropsychological status in psychogenic subtypes.
  

  Scott B, Strutt A, Lundberg-Love P, Schmitt A, Jankovic J, Bowers D

• Hemidystonia associated with Alexander disease.
  

  Vijayakumar D, Lewis RA, Fuller GN, Dhar SU, Machol K, Robak L, et al.

American Academy of Neurology (AAN)
69^th Annual Meeting in Boston, Mass. (April 22-28, 2017)

• A phase 2, open-label, dose-escalating study to evaluate the safety and preliminary efficacy of daxibotulinumtoxinA for injection (RT002) in isolated cervical dystonia.
  

  Comella C, Brashear A, Jankovic J, Patel A, Truong D, Evatt M, et al.

• Clinical relevance of treatment with onabotulinumtoxinA in patients with cervical dystonia: Results from the CD Probe study.
  

  Mari Z, Dashtipour K, Jankovic J, Adler CH, Schwartz M, Brin MF

• Presentation, diagnostic hurdles, and therapeutic measures in a case of isolated coccidioidomycosis meningitis in an immunocompetent individual.
  

  Samudralwar R, Kass J, Bellows S, Goldsmith C

• Assessment of capacity to consent in a Huntington disease clinical trial: Implications for future clinical trial design in neurodegenerative disease populations.
  

  Testa C, Edmondson M, Agarwal P, Blindauer K, Gray C, Jankovic J, et al.

International Neurotoxin Association (INA)
Toxins 2017 3^rd International Conference in Madrid, Spain (Jan. 18-21, 2017)

• A phase 2, open-label, dose-escalating study to evaluate the safety and preliminary efficacy of daxibotulinumtoxina for injection (RT002) in isolated cervical dystonia.
  

  Comella CL, Brashear A, Jankovic J, Patel AT, Truong DD, Chung CY, et al.

• Clinical relevance of treatment with onabotulinumtoxina in patients with cervical dystonia: Results from the CD Probe study.
  

  Dashtipour K, Mari Z, Jankovic J, Adler CH, Schwartz M, Brin MF Dashtipour K, et al.

• Potential new uses of botulinum toxin injections in movement disorders.
  

  Jankovic J

• Predictors of onabotulinumtoxinA response in patients with cervical dystonia.
  

  Jankovic J, Schwartz M, Manack Adams A

Movement Disorder Society (MDS)
20^th International Congress of Parkinson's Disease and Movement Disorders in Berlin, Germany (June 19-23, 2016)

• Understanding, predicting, and preventing falls in progressive supranuclear palsy.
  

  Bluett BR, Litvan I, Cheng S, Juncos J, Bordelon Y, Riley DE, et al.

• Objectives of the MDS rare movement disorders study group.
  

  Gatto EM, Albanese A, Bathia K, Cardoso F, Cesarini M, Chade A, et al.

• A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome.
  

  Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy TK, Shprecher D, et al.

• Predictors of onabotulinumtoxinA treatment response in patients with cervical dystonia.
  

  Jankovic J, Marc S, Aubrey A

• Apraclonidine in blepharospasm.
  

  Jankovic J, Vijayakumar D, Wijemanne S

• Apraclonidine in the treatment of ptosis.
  

  Wijemanne S, Vijayakumar D, Jankovic J

American Academy of Neurology (AAN)
68^th Annual Meeting in Vancouver, BC, Canada (April 15-21, 2016)

• A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome.
  

  Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy T, Shprecher D, et al.

• Paradoxical worsening dystonia after deep brain stimulation in a patient with neurodegeneration with brain iron accumulation.
  

  Tarakad A, Jimenez Shahed J

Movement Disorder Society (MDS)
19^th International Congress of Parkinson's Disease and Movement Disorders in San Diego, Calif. (June 14-18, 2015)

• XCiDaBLE: Observational, prospective trial evaluating Xeomin (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the USA.
  

  Fernandez HH, Jankovic J, Pagan F, Greeley D, Sethi K, Verma A

• Progressive supranuclear palsy and statin use.
  

  Fuentes A, Standaert D, Marras C, Riley D, Hall D, Kluger B, et al.

• DBS experience at a tertiary care referral center.
  

  Jimenez-Shahed J, Keller J, Hunter C, Jankovic J

• American multiple system atrophy natural history study.
  

  Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, et al.

• Cervical dystonia and work productivity: Results from the cervical dystonia patient registry for the observation of onabotulinumtoxinA efficacy.
  

  Molho ES, Stacy M, Gillard P, Charles D, Adler CH, Jankovic J, et al.

• Dystonia-spasticity in a patient with a novel SLC25A12 mutation.
  

  Parnes M, Robak L, Shulman JM, Stocco A, Jankovic J

• Clinical utility of apraclonidine in ptosis.
  

  Wijemanne S, Jankovic J

American Academy of Neurology (AAN)
67^th Annual Meeting in Washington, DC (April 18-25, 2015)

• Reliability of the severity subscale of the revised Toronto Spasmodic Torticollis Rating Scale (TWSTRS-2).
  [Oral Presentation]
  

  Comella C, Perlmutter J, Jinnah H, Factor S, Goetz C, Adler C, et al.

• XCiDaBLE: An observational, prospective trial evaluating Xeomin (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the United States - Final results from the blepharospasm cohort.
  

  Fernandez HH, Jankovic J, Holds J, Lin D, Burns J, Sethi K, et al.

• The impact of cervical dystonia on work productivity: An analysis from the CD Patient Registry for the Observation of OnabotulinumtoxinA Efficacy (CD PROBE).
  

  Molho E, Stacy M, Gillard P, Charles P, Adler C, Jankovic J, et al.

• Dystonia-spasticity in a patient with a novel SLC25A12 mutation.
  

  Parnes M, Robak L, Shulman J, Stocco A, Jankovic J

• SUNCT responding to botulinum toxin.
  

  Wijemanne S, Jankovic J

International Neurotoxin Association (INA)
Toxins 2017 2^nd International Conference in Lisbon, Portugal (Jan. 14-17, 2015)

• Treatment patterns and patient disposition in the cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE).
  

  Comella C, Charles D, Jankovic J, Stacy M, Schwartz M, Manack Adams A, et al.

• Long-term effects of botulinum toxin injections.
  

  Jankovic J

Movement Disorder Society (MDS)
18^th International Congress of Parkinson's Disease and Movement Disorders in Stockholm, Sweden (June 8-12, 2014)

• Treatment patterns and patient disposition in the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE).
  

  Charles D, Jankovic J, Adler CH, Comella C, Stacy M, Schwartz M, et al.

• Convergent validity of the revised motor and psychiatric TWSTRS modules of the Comprehensive Cervical Dystonia Rating Scale (CCDRS).
  

  Comella CL, Perlmutter JS, Jinnah HA, Factor S, Waliczek TA, Rosen AR, et al.

• Effectiveness and safety in the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE).
  

  Jankovic J, Adler CH, Charles D, Comella C, Stacy M, Schwartz M, et al.

• MER vs. MRI guidance in placement of DBS electrodes for Parkinson's disease.
  

  Jimenez-Shahed J, York M, Smith-Gloyd EM, Jankovic J, Viswanathan A

• Methodology for a symptomatic impact study using a portable essential tremor (ET) monitor to direct therapeutic interventions.
  

  Vittal P, Pulliam CL, Goetz CG, Jankovic J, Ramirez-Castaneda JL, Heldman DA

• Reliability and validity of the revised TWSTRS psychiatric module (TWSTRS-PSYCH) of the Comprehensive Cervical Dystonia Rating Scale (CCDRS).
  

  Zurowski MJ, McDonald W, Comella CL, Perlmutter JS, Jinnah HA, Factor S, et al.

American Academy of Neurology (AAN)
66^th Annual Meeting in Philadelphia, Penn. (April 26 - May 3, 2014)

• Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE): Treatment patterns and subject disposition.
  

  Charles P, Jankovic J, Comella C, Stacy M, Schwartz M, Manack A, et al.

• Clinimetric testing of the modules for the Comprehensive Cervical Dystonia Rating Scale (CCDRS).
  [Platform Presentation]
  

  Comella C, Perlmutter J, Jinnah H, Adler C, Barbano R, Factor S, et al.

• Treatment outcomes in Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE).
  

  Jankovic J, Adler C, Charles P, Comella C, Stacy M, Schwartz M, et al.

• Alleviating maneuvers (sensory tricks) in cervical dystonia.
  

  Patel N, Hanfelt J, Marsh L, Jankovic J

• Dopamine transporter imaging in essential tremor with and without parkinsonian features.
  [Platform Presentation]
  

  Waln O, Wu Y, Perlman R, Van AK, Wendt J, Jankovic J

• Hereditary spastic paraplegia due to a novel mutation in SPG11 gene presenting as dopa responsive dystonia, parkinsonism and spasticity.
  

  Wijemanne S, Jankovic J

American Neurological Association (ANA)
138^th Annual Meeting in New Orleans, La. (Oct. 13-15, 2013)

• Efficacy and safety of IPX066, a carbidopa-levodopa, extended-release formulation, in early Parkinson's disease.
  

  Pahwa R, Ellenbogen A, Kell S, O'Conell M, Hauser R, Fahn S, et al.

Movement Disorder Society (MDS)
17^th International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia (June 16-20, 2013)

• The long-term safety and efficacy of thalamic deep brain stimulation in essential tremor.
  

  Baizabal-Carvallo JF, Kagnoff M, Jimenez-Shahed J, Fekete R, Jankovic J

• Minimal clinically important changes in UPDRS scores in early PD in rotigotine clinical trials.
  

  Hauser R, Surmann E, Rubin Z, Jankovic J

• Continuous home monitoring of essential tremor using motion sensors.
  

  Heldman D, Pulliam C, Eichenseer S, Goetz C, Waln O, Hunter C, et al.

• Cervical Dystonia Patient Registry for Observation of onaBotulinumtoxinA Efficacy (CD PROBE): Baseline demographic and clinical characteristics.
  

  Jankovic J, Charles D, Adler C, Comella C, Stacy M, Schwartz M, et al.

• Sensory tricks (corrective maneuvers) in cervical dystonia.
  

  Patel N, Hanfelt J, Marsh L, Jankovic J, for the Dystonia Coalition

• Safinamide significantly improves responder rates in fluctuating Parkinson's disease (PD) patients as add-on to levodopa (SETTLE).
  

  Schapira AHV, Fox SH, Hauser RA, Jankovic J, Jost W, Kulisevsky J, et al.

• Long-term safety of neurotrophic factor gene therapy using AAV2-neurturin (CERE-120) in Parkinson's disease.
  

  Taylor R, Baumann T, Marks Jr W, Ostrem J, Verhagen L, Stacy M, et al.

American Academy of Neurology (AAN)
65^th Annual Meeting in San Diego, Calif. (March 16-23, 2013)

• Movement disorders in golfers.
  

  Dhungana S, Jankovic J

• XCiDaBLE: An observational, prospective trial evaluating Xeomin (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the United States - Interim results from the first 145 subjects with cervical dystonia.
  

  Fernandez H, Pagan F, Danisi F, Greeley D, Jankovic J, Verma A, et al.

• Cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE): Baseline demographic and clinical characteristics.
  

  Jankovic J, Charles P, Adler C, Comella C, Stacy M, Schwartz M, et al.

• Continuous home monitoring of essential tremor using motion sensors.
  

  Pulliam CL, Eichenseer S, Goetz C, Waln O, Hunter C, Jankovic J, et al.

• Long-term efficacy, safety, and side effect profile of botulinum toxin injections in dystonia - a 20-year follow-up.
  

  Ramirez Castaneda J, Jankovic J

• Safinamide add on to L-dopa: A randomized, placebo-controlled, 24-week global trial in patients with Parkinson's disease (PD) and motor fluctuations (SETTLE).
  

  Schapira A, Fox S, Hauser R, Jankovic J, Jost W, Kulisevsky J, et al.

• Zolpidem improves tardive dyskinesia with and without akathisia.
  

  Waln O, Jankovic J

• Clinical and imaging data in essential tremor with parkinsonian features.
  

  Waln O, Wendt J, Van AK, Jankovic J

• The long-term efficacy and safety of fluphenazine in patients with Tourette syndrome.
  

  Wijemanne S, Jankovic J

International Neuropsychological Society (INS)
41^st Annual Meeting in Montreal, Waikoloa, Hawaii (Feb. 6-9, 2013)

• Frontostriatal changes detected by DTI tractography in Parkinson's disease dementia.
  

  Wu TC, Wilde EA, Karmonik C, Yallampalli R, Strutt AM, Jankovic J, et al.

Baylor College of Medicine (BCM)
Current Neurology 2012 in Houston, Texas (Nov. 3-4, 2012)

• Movement disorders in golfers - Four case reports and a brief review of literature.
  

  Dhungana S, Jankovic J

• GABA_B receptor limbic encephalitis: Case report and a brief literature review.
  

  Dhungana S, Nunez-Wallace KR, Van Hook C, Tarakad A, Kass JS

American Neurological Association (ANA)
137^th Annual Meeting in Boston, Mass. (Oct. 7-9, 2012)

• Clinical assessment of the effect of tetrabenazine on motor function in moderate Huntington disease.
  

  Fekete R, Davidson A, Jankovic J

• A prospective, observational trial evaluating Xeomin (incobotulinumtoxinA) for cervical dystonia (CD) or blepharospasm in the United States - Preliminary baseline results on the health impact of CD on patients using the cervical dystonia impact profile (CDIP).
  

  Jankovic J, Thomas M, Vasquez A, Sethi KD, Verma A, Pappert EJ, et al.

• A prospective, observational trial evaluating Xeomin [IncobotulinumtoxinA] for cervical dystonia or blepharospasm in the US - Preliminary baseline results for patients with blepharospasm.
  

  LeDoux MS, Jankovic J, Sethi KD, Verma A, Pappert EJ, Fernandez HH

• Mutations in the novel protein PRRT2 cause infantile convulsions with paroxysmal kinesigenic dyskinesia.
  

  Lee H-Y, Huang Y, Bruneau N, Roll P, Roberson EDO, Hermann M, et al.

Movement Disorder Society (MDS)
16^th International Congress of Parkinson's Disease and Movement Disorders in Dublin, Ireland (June 17-21, 2012)

• Flu-like and systemic symptoms following treatment with botulinum toxins.
  

  Baizabal Carvallo JF, Suresh K, Hunter C, Jankovic J

• AAV2-Neurturin (CERE-120) and Parkinson's disease: The safety and feasibility of combined substantia nigral and putaminal stereotactic targeting via a phase 1/2b clinical trial in advanced Parkinson's disease.
  

  Baumann T, Lang AE, Lozano AM, Olanow CW, Boulis N, Turner D, et al.

• Cervical dystonia subtypes baseline results from the cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE).
  

  Charles PD, Stacy M, Jankovic J, Schwartz M, Brin M, Papapetropoulos S (on behalf of the CD PROBE Study Group)

• Clinical assessment of the effect of tetrabenazine on motor function in moderate Huntington's disease.
  

  Fekete R, Davidson A, Jankovic J

• XCiDaBLE: A phase 4, observational, prospective trial evaluating incobotulinumtoxinA for cervical dystonia (CD) or blepharospasm in the United States - Preliminary baseline results on the health impact of CD on patients using the cervical dystonia impact profile.
  

  Jankovic J, Thomas M, Vasquez A, Sethi K, Verma A, Pappert EJ, et al.

• XCiDaBLE: A phase 4, observational, prospective trial evaluating incobotulinumtoxinA for cervical dystonia or blepharospasm in the United States - Preliminary baseline results for patients with blepharospasm.
  

  LeDoux MS, Jankovic J, Sethi K, Verma A, Pappert EJ, Fernandez HH

• Analysis of CYP2D6 genotype and response to tetrabenazine.
  

  Mehanna R, Hunter C, Davidson A, Ondo W, Jimenez-Shahed J, Jankovic J

• Globus pallidus deep brain stimulation for refractory idiopathic restless legs syndrome.
  

  Ondo WG, Jankovic J, Jimenez-Shahed J

• Neuroprotection by neuropeptide orexin A in a cellular model of Parkinson's disease.
  

  Pan T, Wu Y, Zhu JX, Jankovic J

• Entropy measurements in pallidal neurons in dystonia and Parkinson disease.
  

  Sanghera MK, Darbin O, Alam M, Friehs J, Friehs G, Jankovic J, et al.

• Concomitant use of antidepressants and neuroleptics with tetrabenazine during treatment of Huntington's disease.
  

  Shen V, Clarence-Smith K, Hunter C, Jankovic J

• Long-term safety and efficacy of tetrabenazine in the treatment of chorea associated with Huntington's disease.
  

  Shen V, Clarence-Smith K, Hunter C, Jankovic J

• Tetrabenazine for moderate vs. severe/disabling chorea associated with Huntington's disease.
  

  Shen V, Clarence-Smith K, Hunter C, Jankovic J

• Anti-parkinsonian effects of Nurr1 activator in UPS impairment induced animal model of Parkinson's disease.
  

  Zhang Z, Xie W, Hintermann S, Jankovic J, Le W

American Academy of Neurology (AAN)
64^th Annual Meeting in New Orleans, La. (April 21-28, 2012)

• Flu-like and systemic symptoms following treatment with botulinum toxins.
  

  Baizabal Carvallo J, Jankovic J

• Severity of cervical dystonia: Baseline characteristics from the Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CDPROBE).
  

  Charles P, Jankovic J, Adler C, Brin M, Stacy M, Schwartz M, et al.

• Concomitant use of antidepressants and neuroleptics with tetrabenazine during treatment of Huntington's disease (HD).
  

  Clarence-Smith K, Shen V, Hunter C, Jankovic J

• IncobotulinumtoxinA (Xeomin®) is well tolerated for the treatment of blepharospasm when injected according to patient needs.
  

  Evidente VG, Brodsky M, Gollomp S, Marx M, Hanschmann A, Jankovic J

• Analysis of the behavioral features conferred by the intermediate allele for Huntington disease in the prospective Huntington at risk observational study (PHAROS).
  

  Killoran A, Biglan K, Jankovic J, Eberly S, Kayson E, Oakes D, et al.

• XCiDaBLE: A phase 4, observational, prospective trial evaluating Xeomin (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the United States - Preliminary baseline disease severity and quality of life data.
  

  LeDoux M, Lin D, Jankovic J, Pappert E, Verma A, Sethi K, et al.

• Dystonic respiratory dysregulation and other breathing disorders associated with dystonia.
  

  Mehanna R, Jankovic J

• Genome-wide association study of Gilles de la Tourette Syndrome.
  

  Scharf J, Yu D, Mathews C, Neale B, Stewart E, Fagerness J, et al.

• Long-term safety and efficacy of tetrabenazine in the treatment of chorea associated with Huntington's disease.
  

  Shen V, Clarence-Smith K, Hunter C, Jankovic J

• Tetrabenazine for moderate vs. severe/disabling chorea associated with Huntington's disease (HD).
  

  Shen V, Clarence-Smith K, Hunter C, Jankovic J

• Diagnostic reliability of DaTscan in movement disorders.
  

  Waln O, Jimenez Shahed J, Juliet Wendt, York M, Baizabal Carvallo J, Mehanna R, et al.

Society for Neuroscience (SFN)
41^st Annual Meeting in Washington, DC (Nov. 12-16, 2011)

• Horizontal and vertical eye movements in Huntington's disease patients and age matched controls.
  

  Red S, Ing J, Jeter CB, Hood AJ, Patel SS, Jankovic J, et al.

American Neurological Association (ANA)
136^th Annual Meeting in San Diego, Calif. (Sept. 25-27, 2011)

• Association of PSP with chemical occupational exposure factors.
  

  Litvan I, Cunningham CR, Lees P, Jackson L, Juncos J, Riley D, et al.

European Federation of Neurological Societies (EFNS)
15^th Congress in Budapest, Hungary (Sept. 10-13, 2011)

• Sustained efficacy of long-term incobotulinumtoxin-a (Xeomin®; botulinum neurotoxin type-a, free from accessory proteins) treatment for cervical dystonia, blepharospasm and upper limb post-stroke spasticity.
  

  Truong DD, Brodsky MA, LeWitt PA, Gollomp SM, Kanovsky P, Pulte I, et al.

Movement Disorder Society (MDS)
15^th International Congress of Parkinson's Disease and Movement Disorders in Toronto, Canada (June 5-9, 2011)

• Deep brain stimulation: Hardware related complications in patients with movement disorders.
  

  Baizabal Carvallo JF, Mostile G, Almaguer M, Davidson A, Simpson R, Jankovic J

• The long-term impact of early versus delayed treatment with rotigotine transdermal system in patients with early-stage, idiopathic Parkinson's disease.
  

  Boroojerdi B, Watts RL, Jankovic J, Surmann E, Ghys L

• IncobotulinumtoxinA (NT-201) injections are safe and effective in adult subjects with blepharospasm across dosing intervals in a repeated dose-study.
  

  Brodsky M, Jankovic J, Evidente VGH, Fernandez HH, Grafe SK

• The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism.
  

  Brown CH, Ha AD, York MK, Jankovic J

• Correlation of patient impression with the cervical dystonia impact questionnaire.
  

  Charles PD, Jankovic J, Stacy M, Adler CH, Comella C, Brin M, et al.

• Convergence spasm in conversion disorders: Prevalence in psychogenic and other movement disorders compared to controls.
  

  Fekete R, Baizabal-Carvallo JF, Ha AD, Jankovic J

• Constant current DBS: A randomized controlled clinical trial in Parkinson's disease: 12 month results.
  

  Gallo BV, Okun MS, Mandybur G, Arle J, Elias J, Ford B, et al.

• Essential tremor quantification during activities of daily living.
  

  Heldman DA, Filipkowski D, Jankovic J, Vaillancourt D, Prodoehl J, Elble RJ, et al.

• Identification of a novel downstream target of Nurr1 transcription factor for midbrain dopamine neuron development.
  

  Hen X, Li L, Zhang X, Jankovic J, Le W

• Cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE): Study design of a prospective observational registry.
  

  Jankovic J, Stacy M, Charles PD, Adler CH, Comella C, Brin M, et al.

• A mechanistic study of proteasome inhibition-induced iron misregulation in dopaminergic neuron degeneration.
  

  Li X, Xie W, Jankovic J, Le W

• Amplitude fluctuations in essential tremor. A prospective study.
  

  Mostile G, Fekete R, Giuffrida JP, Yaltho T, Davidson A, Nicoletti A, et al.

• A randomized controlled trial of constant current DBS active stimulation versus off stimulation in Parkinson's disease.
  

  Okun MS, Gallo BV, Mandybur G, Arle J, Elias J, Ford B, et al.

• Efficacy and safety of IPX066, a new carbidopa-levodopa (CD-LD) extended-release formulation, in LD-naive early Parkinson's disease (APEX-PD trial).
  

  Pahwa R, Ellenbogen A, Jankovic J, Hauser R, Fahn S, Clinical Team at Impax Pharmaceuticals

• Patients' perspective of tetrabenazine two years after FDA approval.
  

  Palao AM, Hunter CB, Jankovic J

• Alpha-synuclein: Possible link between Parkinson's disease and melanoma.
  

  Pan T, Zhu J, Li X, Jankovic J

• Brain glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG33 repeat length in the Huntington's disease gene.
  

  Squitieri F, Esmaeilzadeh M, Ciarmiello A, Jankovic J

• Postural instability and gait difficulty scores from the MDS-UPDRS.
  

  Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Tilley BC

• Assessing dissociative pathology in psychogenic movement disorders: Clinical utility of the Dissociative Experiences Scale-II.
  

  Strutt AM, Scott BM, Ferrara J, York MK, Jankovic J

• Safety data in a randomized controlled trial of constant current deep brain stimulation versus lead placement alone for treatment of motor fluctuations in Parkinson's disease.
  

  Tagliati M, Gallo BV, Mandybur G, Arle J, Elias J, Ford B, et al.

• Peripheral trauma and movement disorders: A systematic review of reported cases.
  

  van Rooijen DE, Geraedts EJ, Marinus J, Jankovic J, van Hilten JJ

American Academy of Neurology (AAN)
63^rd Annual Meeting in Honolulu, Hawaii (April 9-16, 2011)

• Deep brain stimulation system revision, and hardware related complications in 512 patients with movement disorders.
  

  Baizabal Carvallo JF, Mostile G, Simpson R, Almaguer M, Davidson A, Jankovic J

• Cervical dystonia patient registry for observation of BOTOX® efficacy (CD PROBE): Interim results of pain-related outcomes.
  

  Charles P, Adler CH, Stacy M, Comella C, Jankovic J, Boo LM, et al.

• Efficacy and safety of repeated incobotulinumtoxin A injections in subjects with cervical dystonia previously treated with botulinum toxin.
  

  Evidente VG, Truong D, Fernandez H, Comella C, Brodsky M, Jankovic J, et al.

• Efficacy and safety of repeated incobotulinumtoxin A injections in subjects with cervical dystonia previously naive to botulinum toxin treatment.
  

  Fernandez H, Comella C, Brodsky M, Evidente VG, Jankovic J, Truong D, et al.

• Intermediate CAG repeats: Analysis of the cooperative Huntington's observational research trial.
  

  Ha AD, Davidson A, Jankovic J

• Essential tremor quantification during activities of daily living.
  

  Heldman D, Filipkowski D, Jankovic J, Vaillancourt D, Prodoehl J, Elble R, et al.

• Cervical dystonia patient registry for observation of BOTOX® efficacy (CD PROBE): Interim results of physician-reported outcomes.
  

  Jankovic J, Charles P, Adler CH, Stacy M, Comella C, Boo LM, et al.

• Double-blind, placebo-controlled fixed-dose trial of IPX066, a novel carbidopa-levodopa (CD-LD) extended-release formulation, in early Parkinson's disease (APEX-PD).
  

  Pahwa R, Hauser R, Jankovic J, Nausieda P, Ellenbough A, Hsu A, et al.

• AMPK-mediated neuroprotection on cellular models of Parkinson's disease.
  

  Pan T, Li X, Zhu J, Le W, Jankovic J

• Cervical dystonia patient registry for observation of BOTOX® efficacy (CD PROBE): Interim results of patient-reported outcomes.
  

  Stacy M, Charles P, Adler CH, Comella C, Jankovic J, Boo LM, et al.

• Postural instability and gait difficulty scores from the MDS-UPDRS.
  

  Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Tilley BC

• Psychosocial profiles of psychogenic movement disorder patients with non-epileptic seizures and other abnormal motor manifestations.
  

  Strutt AM, Scott BM, Ferrara JM, York MK, Jankovic J

• Diffusion tensor tractography of the internal capsule in depressed and anxious Parkinson's disease patients.
  

  York M, Yallampalli R, Gallander K, Strutt A, Chu Z, Karmonik C, et al.

AD/PD
10^th International Congress on Alzheimer's and Parkinson's Diseases in Barcelona, Spain (March 9-13, 2011)

• Diffusion tensor tractography of the internal capsule differentiates stages of cognitive impairment in Parkinson's disease.
  

  York M, Yallampalli R, Gallander K, Strutt A, Chu Z, Karmonik C, et al.

Movement Disorder Society (MDS)
14^th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina (June 13-17, 2010)

• Longitudinal analysis of intermediate CAGn repeat length expansion in the prospective Huntington's disease at-risk observational study (PHAROS).
  

  Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D, Young AB, et al.

• CD-PROBE (cervical dystonia patient registry for observation of BOTOX® efficacy) — preliminary safety data.
  

  Charles D, Adler C, Comella C, Jankovic J, Stacy M, Kurth M, et al.

• Validation of a cervical dystonia questionnaire (CDQ).
  

  Davidson AL, Hunter C, Jankovic J

• Prospective 5-year natural history study of probable multiple system atrophy (MSA) in 175 North American subjects.
  

  Gilman S, Low P, May S, Tanner C, Stern M, Sandroni P, et al.

• Safety and efficacy of repeated NT 201 (botulinum neurotoxin type A free from complexing proteins) injections of patients with blepharospasm.
  

  Grafe S, Hanschmann A, Jankovic J, Comella C

• Validation of a motor screen for undiagnosed parkinsonism: The Baylor Functional Assessment Screen (BFAS).
  

  Hunter CB, York MK, Jankovic J

• CD-PROBE (cervical dystonia patient registry for observation of BOTOX® efficacy) — CD impact on quality of life (QOL) and patient reported outcomes (PRO).
  

  Kurth M, Adler C, Comella C, Charles D, Jankovic J, Stacy M, et al.

• Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease.
  

  Li C, Xie W, Jankovic J, Le W

• Use of an interactive voice response system by patients with blepharospasm receiving repeated injections of NT 201 (botulinum neurotoxin type A free from complexing proteins).
  

  Marx M, Grafe S, Jankovic J, Comella C

• Assessing patients' access to tetrabenazine (Xenazine) after FDA approval.
  

  Palao AM, Mostile G, Hunter CB, Jankovic J

• Curcumin accelerates the clearance of mutant alpha-synuclein and injured mitochondria via autophagy induction.
  

  Pan T, Wu Y, Le W, Jankovic J

• SETTLE study design: A 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide as add-on therapy to levodopa in patients with Parkinson's diseases.
  

  Schapira AHV, Fox S, Hauser R, Jankovic J, Kulisevsky J, Pahwa R, et al.

• Neuropsychological assessment of monolingual Spanish speaking Parkinson's disease patients in the United States pre and post STN-DBS.
  

  Strutt AM, Scott BM, Yaltho T, Simpson R, Jankovic J, York MK

• Open-label extension trial assessing the effects of long-term treatment with rotigotine in subjects with early-stage, idiopathic Parkinson's disease: Results from up to 7 years.
  

  Watts RL, Boroojerdi B, Jankovic J, on behalf of the SP702 Study Group

• Retrospective study of the therapeutic effect of deep brain stimulation in multiple system atrophy.
  

  Wu Y, Almaguer MA, Atassi F, Lai EC, Jankovic J, Ondo WG

• Orthostatic tremor: A review of 40 cases.
  

  Yaltho TC, Jankovic J, Ondo WG

American Academy of Neurology (AAN)
62^nd Annual Meeting in Toronto, Canada (April 10-17, 2010)

• Upper face chorea in Huntington disease.
  

  Fekete R, Jankovic J

• Effect of tetrabenazine (TBZ) on motor function in patients with Huntington disease (HD).
  

  Ferrara J, Mostile G, Hunter C, Adam O, Jankovic J

• CD-PROBE (Cervical Dystonia Patient Registry for Observation of BOTOX® Efficacy) — A multicenter, observational study of onabotulinumtoxin A injections in cervical dystonia (CD) patients — Interim patient reported outcome data.
  

  Jankovic J, Adler C, Charles D, Comella C, Stacy M, Kurth M, et al.

• CD-PROBE (Cervical Dystonia Patient Registry for Observation of BOTOX® Efficacy) — A multicenter, observational study of repeated onabotulinumtoxin A injections in cervical dystonia (CD) patients — Preliminary baseline data.
  

  Jankovic J, Adler C, Charles D, Comella C, Stacy M, Kurth M, et al.

• Clinical correlates of eye movements in Huntington disease.
  

  Jeter C, Hood A, Palao A, Patel S, Jankovic J, Sereno A

• Ubiquitin proteasome system impairment mouse model of Parkinson's disease.
  

  Li X, Li C, Xie W, Jankovic J, Le W

• HIF-1α-mediated neuroprotection on MPP+-induced apoptosis in SH-SY5Y cells.
  

  Pan T, Wu Y, Xie W, Le W, Jankovic J

• The natural progression of clinical symptoms in Parkinson's disease may not be faster in the earlier stages: Results from the ADAGIO delayed-start study.
  

  Rascol O, for the ADAGIO investigators

• Open-label extension trial assessing the effects of long-term treatment with rotigotine in subjects with early-stage, idiopathic Parkinson's disease: Results from up to seven years.
  

  Watts R, Boroojerdi B, Jankovic J, on behalf of the SP702 Study Group

• Asian over representation among patients with hemifacial spasm compared to cranial dystonia.
  

  Wu Y, Davidson A, Huang M, Pan T, Jankovic J

• A novel set shifting fMRI task identifies differences in brain activation in Parkinson's disease and healthy controls.
  

  York M, Karmonik C, Burton P, Richards D, Kakkar E, Grossman R, et al.

World Federation of Neurology (WFN)
XVIII World Congress on Parkinson's Disease and Related Disorders in Miami Beach, Fla. (Dec. 13-16, 2009)

• Rasagiline provides symptomatic benefit in early Parkinson's disease (PD).
  

  Jankovic J, ADAGIO Investigators

• Multicenter, randomized, double-blind, sham surgery-controlled study of intraputaminal AAV2-neurturin (CERE-120) for advanced Parkinson's disease (PD).
  

  Marks Jr W, Bartus R, Siffert J, Starr P, Ostrem J, Stacy M, et al.

• Treatment of dysautonomia associated with Parkinson's disease.
  

  Mostile G, Jankovic J

Baylor College of Medicine (BCM)
Current Neurology 2009 in Houston, Texas (Oct. 31 - Nov. 1, 2009)

• Influence of levodopa and psychotropic medication on emotional and physical symptoms of depression before and following STN-DBS for the treatment of Parkinson's disease.
  

  Gallander KM, Strutt AM, Simpson R, Jankovic J, York MK

• Alternating fluency performance following bilateral STN DBS for the treatment of Parkinson's disease.
  

  Marshall DF, Williams AE, Strutt AM, Jankovic J, York MK

Society for Neuroscience (SFN)
39^th Annual Meeting in Chicago, Ill. (Oct. 17-21, 2009)

• AAV2-neurturin (CERE-120) for advanced Parkinson's disease (PD): Efficacy and safety results from a controlled Phase 2 clinical trial.
  

  Siffert J, Marks Jr WJ, Starr PA, Stacey MA, Boulis NM, Vitek JL, et al.

Movement Disorder Society (MDS)
13^th International Congress of Parkinson's Disease and Movement Disorders in Paris, France (June 7-11, 2009)

• Long-term deep brain stimulation for essential tremor: 12- year clinicopathologic follow up and literature review.
  

  DiLorenzo DJ, Jankovic J, Simpson RK, Takei H, Powell SZ

• Double-blind, randomized, placebo-controlled, cross-over trial of pregabalin in essential tremor.
  

  Ferrara FM, Kenney C, Davidson AL, Shinawi L, Kissel AM, Jankovic J

• Impact of STN-DBS on health-related quality of life in patients with Parkinson's disease.
  

  Ferrara JM, Diamond A, Davidson A , Almaguer M, Jankovic J

• Tourette syndrome in adults.
  

  Gelineau-Kattner RN, Jankovic J, Davidson AL

• Efficacy and safety of NT 201 (botulinum neurotoxin type A free from complexing proteins) in treatment-naive cervical dystonia patients.
  

  Grafe S, Comella C, Jankovic J, Truong D, Hanschmann A

• Efficacy and safety of NT 201, botulinum neurotoxin type A free from complexing proteins) in pre-treated cervical dystonia patients.
  

  Grafe S, Comella C, Jankovic J, Truong D, Hanschmann A

• A randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome.
  

  Jankovic J, Jimenez-Shahed J, Brown LW

• Transcription factor PITX3 in Parkinson's disease.
  

  Le W, Nguyen D, Lin W, Rawal P, Ding Y, Xie W, et al.

• Correlation between Kinesia system assessments and clinical TETRAS scores in patients with essential tremor.
  

  Mostile G, Giuffrida JP, A dam OR, Davidson A, Jankovic J

• 17-AAG protects against rotenone-induced apoptosis in SHSY5Y cells via HSP70 induction.
  

  Pan T, Xie W, Jankovic J, Le W

• Resveratrol, a polyphenol found in red wine, protects against rotenone-induced apoptosis through autophagy induction.
  

  Pan T, Xie W, Le W, Jankovic J

• The course of depressive symptoms in early Parkinson's disease.
  

  Ravina B, Elm J, Camicioli R, Como P, Marsh L, Jankovic J, et al.

• Mood differences between women diagnosed with psychogenic movement disorders and psychogenic seizures.
  

  Strutt AM, Ferrara J, Hill S, York MK, Uber-Zak L, Fogel T, et al.

American Academy of Neurology (AAN)
61^st Annual Meeting in Seattle, Wash. (April 25 - May 2, 2009)

• The written and oral administration of the Symbol Digit Modality Test in Huntington disease.
  

  Adam O, Halton S, Mostile G, Jankovic J

• Efficacy and safety of NT 201 (neurotoxin free from complexing proteins) in cervical dystonia.
  

  Comella C, Jankovic J, Truong D, Hanschmann A, Grafe S

• Efficacy and safety of NT 201 (botulinum neurotoxin free from complexing proteins) in blepharospasm.
  

  Jankovic J, Comella C, Hanschmann A, Grafe S

• Rapamycin protects against rotenone-induced apoptosis through autophagy induction in SH-SY5Y cells.
  

  Pan T, Xie W, Rawal P, Jankovic J, Le W

• A controlled study of the long-term cognitive outcome of bilateral subthalamic nucleus deep brain stimulation.
  

  Williams A, Arzola GM, Strutt AM, Simpson R, Jankovic J, York MK

6^th International Congress on Mental Dysfunctions and Other Non-Motor Features in Parkinson's Disease and Related Disorders
Dresden, Germany (Oct. 16-19, 2008)

• Voxel-based diffusion tensor imaging and diffusion tensor tractography for the evaluation of cognitive functioning in Parkinson's disease.
  

  York M, Karmonik C, Wilde E, Kakkar E, Yallampalli R, Strutt A, et al.

American Neurological Association (ANA)
133^rd Annual Meeting in Salt Lake City, Utah (Sept. 21-24, 2008)

• Progressive DA neuron degeneration induced by targeting administration of proteasome inhibitor in SN.
  

  Xie W, Zhu W, Pan T, Jankovic J, Le W

Movement Disorder Society (MDS)
12^th International Congress of Parkinson's Disease and Movement Disorders in Chicago, Ill. (June 22-26, 2008)

• Unusual motor-phonic tic mimicking essential palatal myoclonus (EPM).
  

  Adam OR, Jankovic J

• Correlation between clinical rating of parkinsonian and essential tremor and quantitative assessments.
  

  Aguilar LG, Giuffrida JP, Heldman DD, Jankovic J

• The essential tremor rating assessment scale (TETRAS).
  

  Elble R, Comella C, Fahn S, Hallett M, Jankovic J, Juncos J, et al.

• Spinocerebellar Ataxia 8: Variable phenotype and unique pathogenesis.
  

  Gupta A, Jankovic J

• Evaluation of a Parkinson's disease screening questionnaire for use in a community-based setting.
  

  Hunter CB, Aguilar LG, Nashatizadeh MM, Lay LF, Jankovic J

• The role of dopaminergic medication doses in impulse control disorders (ICD) in Parkinson's disease (PD).
  

  Jimenez-Shahed J, Baker K, Davidson A, Jankovic J

• Expanded study of NURR1 gene expression in patients with Parkinson's disease.
  

  Le WD, Pan T, Xie W, Huang M, Xu P, Zhu W, et al.

• Deep brain stimulation of the subthalamic nucleus for peripherally-induced parkinsonism.
  

  Nashatizadeh MM, Jankovic J

• A randomized, double-blind, placebo-controlled study of atomoxetine for freezing of gait in Parkinson's disease.
  

  Nashatizadeh MM, Jimenez JE, Davidson AL, Jankovic J

• Rapamycin rescues lactacystin-induced dopaminergic neuron injury in vivo.
  

  Pan T, Xie W, Jankovic J, Le WD

• Neuropsychological functioning of Parkinson's disease patients two years post subthalamic nucleus deep brain stimulation surgery.
  

  Strutt AM, Jankovic J, York MK

• Experience with MRI safety and DBS: Data from the National Parkinson Foundation Centers of Excellence.
  

  Tagliati M, Jankovic J, Koss AM, Pagan F, Okun MS, National Parkinson Foundation DBS Working Group

American Academy of Neurology (AAN)
60^th Annual Meeting in Chicago, Ill. (April 12-19, 2008)

• Volume and nature of patient telephone calls in a large movement disorders center.
  

  Adam OR, Aguilar Tabora LG, Ferrara J, Nashatizadeh M, Jankovic J

• Characteristics of Archimedean spiral drawing in patients with psychogenic tremor.
  

  Aguilar Tabora LG, Davidson A, Jankovic J, Ondo WG

• Morbidity associated with psychogenic movement disorders in children.
  

  Ferrara JM, Jankovic J

• Phenomenology of psychogenic movement disorders in children.
  

  Ferrara JM, Jankovic J

• New version of the UPDRS (MDS-UPDRS): Factor analysis.
  

  Goetz CG, Tilley BC, Shaftman SR, Fahn S, Martinez-Martin P, Poewe W, et al.

• Craving for sweets and other compulsive behaviors in patients with Parkinson's disease.
  

  Jimenez-Shahed J, Calhoun K, Davidson A, Jankovic J

• Acamprosate improves impulse control disorders in Parkinson's disease.
  

  Jimenez-Shahed J, Hunter CB, Jankovic J

• Treatment of freezing of gait in Parkinson's disease with deep brain stimulation of the pedunculopontine nucleus.
  

  Nashatizadeh M, Jankovic J

• Role of deferoxamine and autophagy induction in rotenone-induced apoptosis.
  

  Pan T, Li X, Xie W, Jankovic J, Le WD

• Changes in emotional versus physical symptoms of depression following sub-thalamic nucleus deep brain stimulation for Parkinson's disease.
  

  Strutt AM, York MK, Jankovic J

• Hemidystonia-hemiatrophy syndrome.
  

  Wijemanne S, Jankovic J

Movement Disorder Society (MDS)
11^th International Congress of Parkinson's Disease and Movement Disorders in Istanbul, Turkey (June 3-7, 2007)

• Rotigotine transdermal patch as a treatment of nocturnal symptoms in patients with idiopathic Parkinson's disease.
  

  Chaudhuri KR, Jankovic J, Trenkwalder C, Boroojerdi B

• Clinimetric testing of the new UPDRS (MDS-UPDRS) vs. original version.
  

  Goetz CG, Tilley BC, Shaftman S, Stebbins GT, Fahn S, Martinez-Martin P, et al.

• Clinical features of movement disorders in hemochromatosis.
  

  Hall DA, Ringel S, Howard K, Jankovic J

• Deep brain stimulation for tardive dyskinesia and akathisia.
  

  Kenney C, Barbano R, Sheffield KJ, Jankovic J

• Health related quality of life in essential tremor patients undergoing deep brain stimulation.
  

  Kenney C, Diamond AL, Davidson A, Shinawi LM, Jankovic J

• Health related quality of life in Parkinson's disease patients undergoing deep brain stimulation.
  

  Kenney C, Diamond AL, Davidson A, Shinawi LM, Jankovic J

• Switch from an oral dopamine agonist to rotigotine transdermal patch in Parkinson's disease.
  

  LeWitt PA, Patton JM, MacMahon DG, Jankovic J

• Motor and behavioral outcomes after bilateral GPi deep brain stimulation for severe Tourette syndrome.
  

  Shahed J, Poysky J, Kenney C, Simpson R, Jankovic J

• Shoulder pain in Parkinson's disease.
  

  Stamey W, Jankovic J

• The other Babinski sign in hemifacial spasm.
  

  Stamey W, Jankovic J

• The specificity and sensitivity of "applause sign" in differentiating PSP and other parkinsonian syndromes.
  

  Wu J, Sitburana O, Jankovic J

• Brain permeable iron chelators M-30 and AK-28 rescue degenerated nigral dopamine neurons in animal model of PD.
  

  Zhu W, Pan T, Xie W, Jankovic J, Zheng H, Youdim M, et al.

American Academy of Neurology (AAN)
59^th Annual Meeting in Boston, Mass. (April 28 - May 5, 2007)

• Malignant Tourette syndrome.
  

  Cheung MC, Shahed J, Jankovic J

• Three parkin mutations in a family with Parkinson's disease.
  

  Deng H, Le W, Shahed J, Jankovic J

• Autopsy-proven Huntington disease with 29 trinucleotide repeats.
  [Previously Presented]
  

  Kenney C, Powell S, Jankovic J

• Autophagy induction and its neuroprotection on neurotoxin-induced cell injury relevant to Parkinson's disease.
  

  Pan T, Li X, Zhu W, Xie W, Jankovic J, Le W

• Motor overflow, contralateral dystonia and mirror movements in focal hand dystonia.
  

  Sitburana O, Wu LJC, Sheffield KJ, Davidson A, Jankovic J

• Head injury with amnesia and risk of multiple system atrophy (MSA).
  

  Tanner C, Kukrull W, Shults C, Comyns K, Bhudhikanok G, May S, et al.

• Novel brain permeable iron chelators prevent lactacystin induced ubiquitin-proteasome inhibition and degeneration of nigrostriatal dopamine neurons.
  

  Zhu W, Pan T, Xie W, Xu P, Zheng H, Fridkin M, et al.

• Proteasome inhibition in substantial nigra induces sustained dopamine cells degeneration.
  

  Zhu W, Pan T, Zhang X, Xie W, Jankovic J, Le W

8^th International Conference on Alzheimer's and Parkinson's Diseases (ADPD)
Salzburg, Austria (March 14-18, 2007)

• Comparison of neuroprotective and neurorescue capabilities of rasagiline and selegiline, against lactacystin induced nigrostriatal degeneration.
  

  Zhu W, Pan T, Xie W, Xu P, Jankovic J, Youdim MBH, et al.

Movement Disorder Society (MDS)
10^th International Congress of Parkinson's Disease and Movement Disorders in Kyoto, Japan (Oct. 30 - Nov. 2, 2006)

• Examination of LRRK2 I2012T, G2019S, and I2020T mutations in patients with essential tremor.
  

  Deng H, Le W, Davidson AL, Xie W, Jankovic J

• The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor.
  

  Diamond A, Shahed J, Jankovic J

• Deep brain stimulation of the subthalamic nucleus on Parkinson's disease: Effects on quality of life.
  

  Diamond AL, Vuong KD, Jankovic J

• Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population.
  

  Hunter CB, Tan EK, Lee J, Shinawi LM, Fook-Chong S, Jankovic J

• Hyperhidrosis due to thalamic deep brain stimulation in a patient with essential tremor.
  

  Kenney C, Diamond AL, Jankovic J

• Clinical features that distinguish psychogenic and essential tremor.
  

  Kenney C, Diamond AL, Mejia N, Hunter CB, Jankovic J

• Short-term effects of tetrabenazine on chorea associated with Huntington disease.
  [Previously Presented]
  

  Kenney C, Hunter CB, Davidson A, Jankovic J

• Autopsy-proven Huntington disease with 29 trinucleotide repeats.
  

  Kenney C, Powell S, Jankovic J

• Enhancement of autophagy and neuroprotection by rapamycin in lactacystin-induced injury of dopaminergic neurons.
  

  Pan T, Kondo S, Zhu W, Xie W, Jankovic J, Le W

• Executive dysfunction and comorbid conditions in Tourette syndrome.
  

  Poysky J, Khan H, Krull K, Jankovic J

• Craving sweets in Parkinson's disease.
  

  Shahed J, Davidson A, Jankovic J

• GPI deep brain stimulation for Tourette syndrome improves tics and psychiatric co-morbidities.
  

  Shahed J, Poysky J, Kenney C, Simpson Jr RK, Jankovic J

• Overflow, contralateral and mirror hand dystonia.
  

  Sitburana O, Jankovic J

• Hemiparkinsonism-hemiatrophy syndrome.
  

  Wijemanne S, Jankovic J

• Different faces of hemifacial spasm: Etiological classification.
  

  Wu LJC, Jankovic J

• Runner's dystonia.
  

  Wu LJC, Jankovic J

• Relationship of MRI localization and cognition in DBS.
  

  York MK, Wilde E, Simpson Jr RK, Jankovic J

American Neurological Association (ANA)
131^st Annual Meeting in Chicago, Ill. (Oct. 8-11, 2006)

• Examination of LRRK2 I2012T, G2019S, and I2020T mutations in patients with essential tremor.
  

  Deng H, Le W, Guo Y, Hunter CB, Xie W, Huang M, et al.

• A Mexican pedigree with Parkinson's disease, essential tremor and bell's palsy associated with parkin but not HS1BP3 gene mutation.
  

  Deng H, Le W, Hunter CB, Xie W, Mejia N, Jankovic J

• Genetic analysis of the SLITRK1 gene in Caucasian patients with Tourette syndrome.
  

  Deng H, Le W, Xie W, Jankovic J

• Deep brain stimulation of the subthalamic nucleus on Parkinson's disease: Effects on quality of life.
  [Previously Presented]
  

  Diamond AL, Vuong KD, Jankovic J

• Medications associated with the onset of tardive dyskinesia.
  

  Hunter CB, Kenney K, Mejia N, Davidson A, Jankovic J

• Short-term effects of tetrabenazine on chorea associated with Huntington disease.
  

  Kenney C, Hunter CB, Davidson A, Jankovic J

American Academy of Neurology (AAN)
58^th Annual Meeting in San Diego, Calif. (April 1-8, 2006)

• Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders.
  

  Kenney C, Simpson Jr RK, Hunter CB, Ondo WG, Almaguer M, Davidson A, et al.

• Long term safety of deep brain stimulation for the treatment of Parkinson's disease.
  

  Kenney CJ, Vuong K, Hunter C, Almaguer M, Jankovic J

• Nurrl deficiency predisposes to apoptosis induced by lactacystin in SH-SY5Y cells in vitro.
  

  Pan T, Xie W, Deng H, Zhao H, Jankovic J

• Bilateral GPI deep brain stimulation for Tourette syndrome.
  

  Shahed J, Poysky J, Kenney C, Simpson Jr RK, Jankovic J

• Frontostriatal cognitive functioning 6 months following bilateral subthalamic nucleus deep brain stimulation.
  

  York MK, Jankovic J, Lai EC, Dulay M

International Neuropsychological Society (INS)
34^th Annual Meeting in Boston, Mass. (Feb. 1-4, 2006)

• Neuropsychological outcome after bilateral deep brain stimulation surgery for advanced Parkinson's disease: Base rates adjusted for practice effects, test unreliability, and natural disease progression.
  

  Dulay MF, York MK, Jankovic J, Simpson Jr RK

American Neurological Association (ANA)
130^th Annual Meeting in San Diego, Calif. (Sept. 25-28, 2005)

• Botulinum toxin type B Observational Study (BOS).
  

  Jankovic J, Hunter CB, the BOS Study Group

American Academy of Neurology (AAN)
57^th Annual Meeting in Miami Beach, Fla. (April 9-16, 2005)

• Genetic analysis of G309D and W4370PA mutations of PINK1 in Parkinson's disease.
  

  Deng H, Le W, Zhang X, Pan T, Jankovic J

• New version of the UPDRS: Development methods and working document for field testing.
  

  Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins G, et al.

• A variant in the HS1-BP3 gene is associated with familial essential tremor.
  

  Higgins JJ, Lombardi RQ, Pucilowska J, Jankovic J, Tan EK, Rooney JP

• Convergence spasm and other psychogenic eye movement disorders.
  

  Mejia NI, Jankovic J

• Tics associated with other disorders.
  

  Mejia NI, Jankovic J

• HSP70 inducer VPA inhibits rotenone-induced apoptosis in SH-SY5Y cells.
  

  Pan T, Xie W, Jankovic J, Le W

• Characteristics of Parkinson's disease in patients with childhood-onset essential tremor.
  [Previously Presented]
  

  Shahed J, Diamond AL, Vuong KD, Jankovic J

• Botulinum toxin treatment for oromandibular dystonia and bruxism in patients with Tourette syndrome.
  

  Silay YS, Jankovic J

Movement Disorder Society (MDS)
9^th International Congress of Parkinson's Disease and Movement Disorders in New Orleans, La. (March 5-8, 2005)

• Gait and balance assessment in parkinsonian disorders.
  

  Azher SN, Vuong KD, Shahed J, Diamond AL, Jankovic J

• Small interfering RNA (SiRNA) targeting the PINK1 induces apoptosis in human SH-SY5Y cells.
  

  Deng H, Jankovic J, Pan T, Xie W, Le W

• Reduced NURR1 gene expression affects expression of dopaminergic phenotypic markers and Parkinson's disease-related genes.
  

  Deng H, Jankovic J, Xie W, Pan T, Le W

• Globus pallidus deep brain stimulation in dystonia.
  

  Diamond AL, Shahed J, Azher SN, Vuong KD, Jankovic J

• Relationship among psychiatric, motor and cognitive functioning in non-demented individuals with Parkinson's disease.
  

  Dulay MF, Levin HS, Jankovic J, Lai EC, York MK

• Tetrabenazine: Does prior history of depression preclude this drug as a treatment option?
  

  Hunter C, Vuong KD, Mejia N, Jankovic J

• Botulinum toxin type B Observational Study (BOS).
  

  Jankovic J, Hunter C, Atassi MZ, Dolimbek BZ, Dolimbek GS, and BOS Research Group

• Prevalence of cervical dystonia and spasmodic torticollis in the United States.
  

  Jankovic J, Tsui J, Bergeron C

• Medications associated with the onset of tardive dyskinesia.
  

  Mejia N, Vuong KD, Hunter C, Jankovic J

• Predictors of battery life for the Activa® Soletra 7426 neurostimulator.
  

  Ondo WG, Meilak C, Vuong KD, Jankovic J

• Subthalamic deep brain stimulation in patients with a previous pallidotomy.
  

  Ondo WG, Silay Y, Almaguer M, Jankovic J

• Characteristics of Parkinson's disease in patients with childhood-onset essential tremor.
  

  Shahed J, Diamond AL, Vuong KD, Jankovic J

• Parkinsonism associated with adalimumab in a patient with rheumatoid arthritis.
  

  Tintner R, Silay YS, Sessoms S, Jankovic J

American Neurological Association (ANA)
129^th Annual Meeting in Toronto, Canada (Oct. 4-5, 2004)

• Botulinum toxin serotype A compared to B in cervical dystonia: Randomized, double-blind, parallel study.
  

  Comella CL, Jankovic J, Leurgans S, Fan W, Chmura T, the Dystonia Study Group

• The safety of deep brain stimulation in patients with Parkinson's disease, essential tremor, and other movement disorders.
  

  Silay Y, Jankovic J, Vuong KD, Almageur M, Ondo WG, Tintner R, et al.

Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders
18^th Annual Symposium in Toronto, Canada (Oct. 3, 2004)

• Safety and efficacy of tetrabenazine in the treatment of Huntington's disease and other choreas.
  

  Jankovic J, Hunter CB, Vuong KD

• The Tremor Rating Scale (TRS).
  

  Tintner R for the Tremor Research Group

Movement Disorder Society (MDS)
8^th International Congress of Parkinson's Disease and Movement Disorders in Rome, Italy (June 13-17, 2004)

• Tetrabenazine, a monoamine depleter, effective in the treatment of Tourette syndrome.
  

  Hunter C, Vuong KD, Mejia N, Jankovic J

• Tetrabenazine: Effective treatment for tardive dyskinesia.
  

  Jankovic J, Hunter C, Mejia N, Vuong KD

• A multicenter, double-blind, placebo-controlled trial of topiramate in essential tremor.
  

  Jankovic J, Ondo WG, Stacy MA, Elble RJ, Pahwa R, Connor GS, et al.

• Nurr1 gene targeting therapy for Parkinson disease.
  

  Le W, Jiang Q, Xie W, Hintermann S, Jankovic J

• The pharmacological and biological effects of pramipexole on dopamine neuron associated genes: DAT, VMAT-2, and Nurr1.
  

  Pan T, Xie W, Jankovic J, Le W

• Young-onset versus late-onset Parkinson's disease: Clinical features and disease progression.
  

  Silver GA, Vuong KD, Jankovic J

• Long-term prognosis of psychogenic movement disorders.
  

  Thomas M, Banuelos P, Vuong KD, Jankovic J

• Psychogenic dystonia: Clinical characteristics and long-term progression.
  

  Thomas M, Vuong KD, Jankovic J

• A double-blind, randomized, parallel group design comparison of botulinum toxin, type A (Botox) and botulinum toxin, type B (Myobloc) on systemic and ocular autonomic symptoms and physiology in patients with cervical dystonia.
  

  Tintner R, Gross RL, Winzer UF, Smalky KA, Jankovic J

• Safety and efficacy of tetrabenazine in childhood hyperkinetic movement disorders.
  

  Vuong KD, Hunter C, Mejia N, Jankovic J

• Is depression a predictor of outcome after bilateral subthalamic deep brain stimulation in patients with Parkinson's disease?
  

  York MK, Silay YS, Chaytor N, Simpson Jr RK, Jankovic J

American Academy of Neurology (AAN)
56^th Annual Meeting in San Francisco, Calif. (April 24 - May 1, 2004)

• Camptocormia: Pathogenesis, classification and response to therapy.
  

  Azher S, Jankovic J

• Interim results of an observational study of neutralizing antibody formation with the current preparation of botulinum toxin type A treatment for cervical dystonia.
  

  Comella CL, Jankovic J, Daggett S, Mordaunt J, Brin MF

• Haplotype analysis at the ETM2 locus in American and Singaporean populations with familial essential tremor.
  

  Higgins JJ, Lombardi RQ, Tan EK, Jankovic J, Pucilowska J, Rooney JP

• Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.
  

  Hunter CB, Vuong KD, Jankovic J

• Essential tremor in children.
  

  Jankovic J, Madisetty J, Vuong KD

• Psychogenic tremor: Long-term outcome.
  

  Jankovic J, Vuong KD, Thomas M

• Effects of ropinirole on progression of parkinsonism in Nurr1-deficient mice and its underlying mechanisms.
  

  Jiang C, Pan T, Jankovic J, Le W

• Dopaminergic properties and anti-parkinsonian effects of IPX750 in rodent models of Parkinson's disease.
  

  Jiang C, Wan X, Jankovic J, Christian S, Sundsmo J, Le W

• The pharmacological and biological effects of pramipexole on dopamine transporter.
  

  Pan T, Jankovic J, Le W

• Decreased Nurr1 mRNA in peripheral blood lymphocytes in Parkinson's disease.
  

  Pan T, Xie W, Jankovic J, Le W

• The efficacy and safety of fluphenazine in patients with Tourette syndrome.
  

  Silay YS, Vuong KD, Jankovic J

• A double-blind, randomized, parallel group design comparison of botulinum toxin, type A (Botox®) and botulinum toxin, type B (Myobloc™) on autonomic symptoms and physiology in patients with cervical dystonia.
  

  Tintner R, Winzer UF, Smalky KA, Jankovic J

American Society for Experimental NeuroTherapeutics (ASENT)
6^th Annual Meeting in Bethesda, Md. (March 11-13, 2004)

• Tetrabenazine in the treatment of chorea.
  

  Jankovic J, Hunter CB, Vuong KD

International Neuropsychological Society (INS)
32^nd Annual Meeting in Baltimore, Md. (Feb. 4-7, 2004)

• Information processing speed influences the component processes of verbal working memory in Parkinson's disease patients.
  

  York MK, Levin HS, Soety EM, Lai EC, Jankovic J, Grossman RG

American Academy of Neurology (AAN)
55^th Annual Meeting in Honolulu, Hawaii (March 29 - April 5, 2003)

• Haplotype analysis of unrelated individuals with familial essential tremor.
  

  Higgins JJ, Jankovic J, Lombardi RQ, Pucilowska J, Tan EK, Ashizawa T, et al.

• Comparison of postoperative improvement of staged bilateral subthalamic stimulation in patients with advanced Parkinson's disease.
  

  Kuniyoshi S, Tintner R, Ondo W, Simpson R, Jankovic J

• Apolipoprotein E controls risk and age at onset of Parkinson disease.
  

  Li Y-J, Martin ER, Scott WK, Haines JL, Nance MA, Hubble JP, et al.

• Glutathione S-Transferase, Omega-1 (GSTO1) modifies age at onset of Alzheimer disease and Parkinson disease.
  

  Li Y-J, Oliveria AS, Hauser MA, Hauser ER, Scott WK, Stenger JE, et al.

• The epidemiology of myoclonus in the medical and surgical intensive care unit (ICU).
  

  Tintner R, Kuniyoshi SM, Gonzalez A, Jankovic J

• Specific mitochondrial haplogroups affect risk for late-onset Parkinson disease.
  

  Van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Haines JL, McLaurin AC, et al.

Movement Disorder Society (MDS)
7^th International Congress of Parkinson's Disease and Movement Disorders in Miami, Fla. (Nov. 10-14, 2002)

• Treatment of hypophonia with collagen vocal fold augmentation in patients with parkinsonism.
  

  Hill AN, Jankovic J, Vuong KD, Donovan D

• Age-related tolerability of tetrabenazine.
  

  Hunter CB, Wang A, Vuong KD, Jankovic J

• Tetrabenazine in the treatment of Tourette syndrome.
  

  Hunter CB, Wang A, Vuong KD, Jankovic J

• Premonitory sensations in tics.
  

  Kwak CH, Jankovic J

• Reduced Nurr1 expression increases the susceptibility to dopaminergic toxins via nitric oxide.
  

  Le W, Imam SZ, Xie W, Ali S, Jankovic J

• Computerized posturography balance assessment of patients with bilateral vim deep brain stimulation.
  

  Ondo WG, Cohen H, Almaguer M, Jankovic J

• Upregulation of Nurr1 gene expression by dopamine receptor agonist pramipexole in human neuroblastoma SHSY-5Y cells.
  

  Pan TH, Xu PY, Xie WJ, Hunter C, Jankovic J, Le WD

• Reliability of limits of stability measures in Parkinson's disease.
  

  Protas EJ, Thomas M, Cunha IT, Caroline KS, Wankadia S, Jankovic J

• Minocycline in Huntington's disease: A pilot study.
  

  Thomas M, Ashizawa T, Jankovic J

• Gait and Balance Scale (GABS): Validation and utilization.
  

  Thomas M, Jankovic J, Suteerawattanon M, Wankadia S, Caroline K, Protas E

• Experience with bilateral subthalamic nucleus (STN) stimulation for Parkinson's disease (PD).
  

  Tintner R, Almaguer M, Sanghera M, Simpson R, Ondo WG, Jankovic J

• Predictors of response to bilateral subthalamic nucleus stimulation for Parkinson's disease.
  

  Tintner R, Almaguer M, Vuong KD, Ondo WG, Jankovic J, Sanghera M

• Pleuropulmonary fibrosis after 11 years of pergolide treatment.
  

  Tintner R, Manian P, Gauthier P, Jankovic J

• The efficacy and safety of Dysport (botulinum type A toxin) in cervical dystonia: Results of the first US study.
  

  Truong DD, Duane DD, Jankovic J, Singer C, Comella CL, the US Dysport Dystonia Study Group

American Neurological Association (ANA)
127^th Annual Meeting in New York City, N.Y. (Oct. 12-16, 2002)

• Dystonia in Friedreich's ataxia.
  

  Hou JG, Jankovic J

Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins
International Conference in Hannover, Germany (June 8, 2002)

• Comparison of immunogenicity of old versus current Botox in cervical dystonia.
  

  Jankovic J, Ahsan J, Vuong KD

American Academy of Neurology (AAN)
53^rd Annual Meeting in Philadelphia, Penn. (May 5-11, 2001)

• The prevalence of restless legs syndrome in patients with Parkinson's disease.
  

  Atassi F, Vuong KD, Jankovic J, Ondo WG

• Exploring the relationship between Parkinson's disease and restless legs syndrome.
  

  Ondo WG, Vuong KD, Jankovic J

Movement Disorder Society (MDS)
6^th International Congress of Parkinson's Disease and Movement Disorders in Barcelona, Spain (June 11-15, 2000)

• Olanzapine treatment for dopaminergic induced hallucinations.
  

  Ondo WG, Hunter C, Vuong KD, Jankovic J

• Daytime sleepiness in patients with Parkinson's disease.
  

  Ondo WG, Vuong KD, Atassi F, Khan H, Kwak C, Jankovic J

American Academy of Neurology (AAN)
52^nd Annual Meeting in San Diego, Calif. (April 29 - May 6, 2000)

• Unilateral thalamic deep brain stimulation for essential tremor and Parkinson's disease: Effects of stimulation on the non-target limb and rebound augmentation.
  

  Vuong KD, Ondo WG, Almaguer M, Simpson RK, Jankovic J

American Academy of Neurology (AAN)
46^th Annual Meeting in Washington, DC (May 1-7, 1994)

• Neuropsychological distinctions between cortico-basal ganglionic degeneration (CBGD) and Alzheimer's disease with extrapyramidal signs.
  

  Massman PJ, Kreiter KT, Jankovic J, Doody RS

International Neuropsychological Society (INS)
22^nd Annual Meeting in Cincinnati, Ohio (Feb. 2-5, 1994)

• Neuropsychological differentiation of corticobasal degeneration from Alzheimer's disease.
  

  Massman PJ, Kreiter KT, Jankovic J, Doody RS

American Neurological Association (ANA)
118^th Annual Meeting in Boston, Mass. (Oct. 18-20, 1993)

• The impact of extended deprenyl treatment in Parkinson's disease patients not requiring levodopa therapy.
  

  Shoulson I, Parkinson Study Group

American Academy of Neurology (AAN)
43^rd Annual Meeting in Boston, Mass. (April 21-27, 1991)

• The alien hand and related signs.
  

  Doody RS, Jankovic J